Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Kempharm Inc

(NASDAQ: KMPH)
Add to Portfolio
-0.05 (-7.81%)
as of Oct 18, 2019

Last 0.59
Change -0.05 (-7.81%)
Open 0.67
Prev. Close 0.64
Today's Range
0.52
0.68
52wk Range
0.52
3.00
Volume 155,700
Avg Volume 121,190
Sector All Sectors By Industry

Perfomance Comparison

Name Today 3-Month 1-Year
KMPH -7.81% -53.93% -76.04%
DJIA -0.95% +1.49% +5.48%
S&P 500 -0.39% +1.64% +7.85%

Key Statistics

Annual EPS -1.93
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 20,200
Weighted Alpha -79.34
Standard Deviation -2.01
Profit Margin N/A
Beta 1.43

Growth Rates

YTD -66.61%
1-Year -76.32%
3-Year -83.94%

Opinion

Sell Hold Buy

Recent Headlines

KemPharm Provides Updates Regarding its Board of

GlobeNewswire via COMTEX - Fri Sep 20, 05:00PM EDT
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that, on September 18, 2019, Danny L. Thompson provided notice of his resignation (full story)
KMPH: 0.59 (-0.05)

KemPharm to Participate in the Oppenheimer Fall Summit

GlobeNewswire via COMTEX - Tue Sep 17, 08:30AM EDT
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will host(full story)
KMPH: 0.59 (-0.05)

KemPharm to Present at the 21st Annual Global

GlobeNewswire via COMTEX - Thu Sep 05, 07:30AM EDT
KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its president and chief executive officer, Travis C. Mickle, Ph.D., will prese(full story)
KMPH: 0.59 (-0.05)

KemPharm Announces Entry into Definitive Collaboration

GlobeNewswire via COMTEX - Wed Sep 04, 08:01AM EDT
Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales(full story)
PTCI: 0.5500 (+0.1500), KMPH: 0.59 (-0.05)

KemPharm Reports Second Quarter 2019 Results

GlobeNewswire via COMTEX - Tue Aug 13, 05:00PM EDT
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the quarter ended June 30, 2019.(full story)
KMPH: 0.59 (-0.05)